Magnesium-containing products and uses thereof

Abstract

A composition including a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH) 2 , at a concentration ranging from 0 to 99 wt %; or Mg(OH) 2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

1 . A composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. 
     
     
         2 . The composition according to  claim 1 , comprising a hydrate form of magnesium oxide selected from the group including:
 a. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and MgO at a concentration ranging from 0 to 99 wt %; or   b. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and Mg(OH) 2 , at a concentration ranging from 0 to 99 wt %; or   c. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n is any value from 0.1 to 2, and Mg(OH) 2  at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.   
     
     
         3 . The composition of  claim 1 , wherein n ranges from 0.3 to 1. 
     
     
         4 . The composition of  claim 1 , wherein a concentration of said MgO.(H 2 O)n is selected from the group including: at least 10 wt %, at least 20 wt %, at least 30 wt %, at least 40 wt %, at least 50 wt %, at least 60 wt %, at least 70 wt % or at least 80 wt % of a total weight of the composition. 
     
     
         5 . The composition of  claim 1 , being in a form of a plurality of particles. 
     
     
         6 . The composition of  claim 1 , having a BET surface area ranging from 30 m 2 /gram to 40 m 2 /gram. 
     
     
         7 . A pharmaceutical composition comprising the magnesium-containing composition of  claim 2 . 
     
     
         8 . The pharmaceutical composition of  claim 7  further comprising at least one additional active agent and a pharmaceutically acceptable carrier. 
     
     
         9 . The pharmaceutical composition of  claim 7  wherein the at least one additional agent is selected from the group including Vitamin D, Vitamin B 6 , and Vitamin E. 
     
     
         10 . The pharmaceutical composition of  claim 7 , being formulated as a unit dosage form for oral administration, wherein an amount of elemental magnesium in said unit dosage form ranges from 50 mg to 2000 mg. 
     
     
         11 . The pharmaceutical composition of  claim 10 , being characterized as capable of generating free magnesium ions from at least 50% of said composition under physiological conditions of a human stomach. 
     
     
         12 . The pharmaceutical composition of  claim 10 , being characterized as generating free magnesium ions from at least 50% of said composition when dissolved in an acidic aqueous solution for 45 minutes at room temperature. 
     
     
         13 . The use of a composition according to  claim 2  in the preparation of a pharmaceutical composition for use in the treatment of a subject in need of magnesium supplementation. 
     
     
         14 . A method of treating a subject in need of magnesium supplementation, the method comprising administering to the subject a therapeutically effective amount of a composition selected from the group consisting of: A composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2; and a pharmaceutical composition comprising a hydrate form of magnesium oxide selected from the group including:
 d. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and MgO at a concentration ranging from 0 to 99 wt %; or   e. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and Mg(OH) 2 , at a concentration ranging from 0 to 99 wt %; or   f. Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration ranging from 1 to 100 wt %, wherein n is any value from 0.1 to 2, and Mg(OH) 2  at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.   
     
     
         15 . The method of  claim 14 , wherein said therapeutically effective amount is equivalent to from 50 to 2000 mg of elemental magnesium per day. 
     
     
         16 . The use of the composition of  claim 1  in the preparation of a pharmaceutical composition for the treatment of a condition or disorder selected from the group consisting of hypomagnesaemia, coronary artery disease (CAD), chronic heart failure, diabetes mellitus, metabolic syndrome, an abnormal muscle excitability, a convulsive disorder, a psychiatric disturbance, a calcium and/or potassium abnormality, a chronic intoxication, alcoholism, drug abuse, renal wasting, stress, neurosis, a nervous disorder, an endocrine-metabolic disorder, malnutrition, constipation, preeclampsia, leg cramps, cerebral palsy, depression, asthma, a cardiovascular disease, an ischemic heart disease, cardiac arrhythmias, hypertension, pregnancy-induced hypertension, stroke, a cerebrovascular disease, osteoporosis, alcohol withdrawal, preterm labor, fatigue, renal stones, kidney stones, headache, migraine, altitude sickness, premenstrual syndrome, fibromyalgia, muscle weakness, insulin resistance, bronchospasms, hyperlipidemia, mitral valve prolapse, and neonatal encephalopathy. 
     
     
         17 . A pharmaceutical composition unit dosage form for oral administration, the composition comprising a magnesium salt selected from the group consisting of magnesium oxide hydrate MgO.(H 2 O)n, wherein n is any value from 0.1 to 2, MgO and Mg(OH) 2 , the composition being characterized as capable of generating free magnesium ions from at least 50% of its magnesium content under physiological conditions of a human stomach. 
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein said magnesium salt is in an amount equivalent to an amount of elemental magnesium that ranges from 50 mg to 2000 mg. 
     
     
         19 . A pharmaceutical composition unit dosage form for oral administration, the composition comprising a magnesium salt selected from the group consisting of magnesium oxide hydrate MgO.(H 2 O)n, wherein n is any value from 0.1 to 2, MgO and Mg(OH) 2  and is being characterized as capable of generating free magnesium ions from at least 80% of its magnesium content when dissolved in an acidic aqueous solution for 45 minutes at room temperature.